Roots Analysis has done a detailed study on Endocannabinoid System Targeted Therapeutics Market, 2020-2030 “ covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key Market Insights
More than 65 industry players across the world are presently engaged in evaluating the clinical applications of over180 cannabinoid-derivatives that target the human endocannabinoid signaling system
The pipeline features a variety of marketed / clinical stage therapies, being investigated for a wide range of target disease indications and designed for administration via different routes
The geographical landscape of this industry is likely to evolve in the next few years as federal authorities legalize the use of medical cannabis across multiple countries
Despite the associated stigma, many organizations have extended financial support to aid research efforts in this domain; the focus is on understanding the clinical benefits of endocannabinoid signaling in different diseases
The growing interest in this field is also reflected by the 170+ partnerships that have been signed in the last five years, involving both international and indigenous stakeholders, across different geographical marketplaces
Presently, North American companies seem to be consolidating their presence indigenously, mostly through strategic acquisitions; key value drivers behind such deals include product and geographical expansion
Future market size, based on revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across a variety of therapeutic areas, target receptors and key geographical regions
For more information, please visit “Endocannabinoid System Targeted Therapeutics Market, 2020-2030.“